Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,155 INR | +1.78% | +0.88% | +6.16% |
Mar. 28 | Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Thursday Trading | MT |
Mar. 28 | Dr. Reddy's Laboratories Signs Deal to Distribute Sanofi's Vaccine Brands | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's enterprise value to sales, at 3.36 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.16% | 12.09B | B+ | ||
+33.46% | 701B | C+ | ||
+26.24% | 571B | B | ||
+0.93% | 381B | C+ | ||
+21.03% | 334B | B- | ||
+17.51% | 319B | C+ | ||
+0.74% | 210B | B+ | ||
+2.95% | 210B | B- | ||
-6.05% | 201B | A+ | ||
-3.61% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Dr. Reddy's Laboratories Limited - Bombay S.E.
- Ratings Dr. Reddy's Laboratories Limited